Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 14;9(5):158.
doi: 10.3390/jcdd9050158.

Practical Approaches to Build and Sustain a Cardio-Oncology Clinic

Angeliki Chasouraki  1 , Christos Kourek  1 , Alexandros Sianis  1 , Konstantinos Loritis  1 , Peggy Kostakou  1 , Elias Tsougos  1 , Ioannis Paraskevaidis  1 , Argyrios Ntalianis  1 , Alexandros Briasoulis  1   2
Affiliations
Review

Practical Approaches to Build and Sustain a Cardio-Oncology Clinic

Angeliki Chasouraki et al. J Cardiovasc Dev Dis. .

Abstract

The therapeutical advances in recent years in the field of oncology treatment have increased survival rates and improved the quality of life of oncology patients, thus turning cancer into a chronic disease. However, most of the new cancer treatments come at the expense of serious cardiovascular adverse events threatening the success story of these patients. The establishment of multidisciplinary medical teams to prevent, monitor, and treat cardiovascular diseases in cancer-treated patients is needed now more than ever. The aim of this narrative review is to demonstrate the existing knowledge and practical approaches on how to establish and maintain a cardio-oncology program for the rising number of patients who need it.

Keywords: cardio-oncology; cardiotoxicity; chemotherapy; heart failure.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Suggested evaluation of patients with malignancies at risk for cardiotoxicity. (Figure 1 is an original figure, also including data from reference [21]).
Figure 2
Figure 2
Steps in planning and developing a cardio-oncology clinic.
See this image and copyright information in PMC

References

    1. Cardinale D., Colombo A., Lamantia G., Colombo N., Civelli M., De Giacomi G., Rubino M., Veglia F., Fiorentini C., Cipolla C.M. Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. JACC. 2010;55:213–220. doi: 10.1016/j.jacc.2009.03.095. - DOI - PubMed
    1. McGowan J.V., Chung R., Maulik A., Piotrowska I., Walker J.M., Yellon D.M. Anthracycline Chemotherapy and Cardiotoxicity. Cardiovasc. Drugs Ther. 2017;31:63–75. doi: 10.1007/s10557-016-6711-0. - DOI - PMC - PubMed
    1. Curigliano G., Cardinale D., Dent S., Criscitiello C., Aseyev O., Lenihan D., Cipolla C.M. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J. Clin. 2016;66:309–325. doi: 10.3322/caac.21341. - DOI - PubMed
    1. Leemasawat K., Phrommintikul A., Chattipakorn S.C., Chattipakorn N. Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: Insights from in vitro, in vivo, and clinical studies in breast cancer patients. Cell. Mol. Life Sci. 2020;77:1571–1589. doi: 10.1007/s00018-019-03340-w. - DOI - PMC - PubMed
    1. Deidda M., Madonna R., Mango R., Pagliaro P., Bassareo P.P., Cugusi L., Romano S., Penco M., Romeo F., Mercuro G. Novel insights in pathophysiology of antiblastic drugs-induced cardiotoxicity and cardioprotection. J. Cardiovasc. Med. 2016;17((Suppl. 1)):e76–e83. doi: 10.2459/JCM.0000000000000373. - DOI - PubMed

LinkOut - more resources